'Hashan De Silva, the managing partner of biotech investment fund KP Rx, says: “In the short term, the share price might continue to struggle if sales growth in the US slows and if Acadia, Neuren’s commercial partner, is slow to launch in other markets.' it seems like others see Daybue's current performance as a short term barrier to higher share price...
'Hashan De Silva, the managing partner of biotech investment...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.86 |
Change
0.510(3.55%) |
Mkt cap ! $1.894B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $14.93 | $14.35 | $1.433M | 97.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 485 | $14.85 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.87 | 400 | 6 |
View Market Depth
| Last trade - 10.51am 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |